Evidence map›Paper›PMID 30122305›Full record

Trial reportLancet (London, England)2018

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding

3 registry-linked trialsAbstract readClinical Trial, Phase IIComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02453711. Cited by 373 papers, 33 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
373citing papers in PubMed, 33 pooled it
43.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02453711 phase2completed

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Ran2015Enrolled957Registered outcomes37Posted comparisons5ConditionsMetabolism and Nutrition Disorder, ObesityArmsliraglutide, Placebo, semaglutide
PMID 30993900other papers from this trial
Open the trial in the graph
NCT04529278 phase2unknown statusstarted 2021, after this paper: background citation

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Ran2021Enrolled18Registered outcomes8Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Hemodialysis, ObeseArmsliraglutide
PMID 29726082PMID 25526642PMID 19853906PMID 18931095PMID 28854085PMID 26283739PMID 24911038PMID 19926371PMID 22383694PMID 24742478PMID 28493926other papers from this trial
Open the trial in the graph
NCT05196958 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)

TypeinterventionalSponsorFondation Hôpital Saint-JosephRan2022 to 2024Enrolled20ConditionsInflammatory Bowel Diseases, Diabetes Mellitus, Type 2ArmsGLP1 analogues
3 · Its place in the literature

Who cites it

373 citing papers in PubMed, 33 syntheses or guidelines pooled it, 778 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

313 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Patrick M O'NeilMedical University of South Carolina, Charleston, SC, USA.
Andreas L BirkenfeldDepartment and Outpatient Department of Medicine III, Carl Gustav Carus University Hospital Dresden, Dresden, Germany.
Barbara McGowanGuy's and St Thomas' NHS Foundation Trust, London, UK.
Ofri MosenzonHadassah Hebrew University Hospital, Jerusalem, Israel.
Sue D PedersenC-endo Diabetes and Endocrinology Clinic, Calgary, AB, Canada.
Sean WhartonYork University and Wharton Weight Management Clinic, Toronto, ON, Canada.
Charlotte Giwercman CarsonNovo Nordisk A/S, Søborg, Denmark.
Cecilie Heerdegen JepsenNovo Nordisk A/S, Søborg, Denmark.
Maria KabischNovo Nordisk A/S, Søborg, Denmark.
John P H WildingObesity and Endocrinology Research, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. Electronic address: j.p.h.wilding@liverpool.ac.uk.
Novo Nordisk (Denmark) · DKGuy's and St Thomas' NHS Foundation Trust · GBLMC Diabetes & Endocrinology (Canada) · CAMedical University of South Carolina · USUniversity Hospital Carl Gustav Carus · DEUniversity of Liverpool · GBYork University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss.

methodsWe did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial. The study was done in eight countries involving 71 clinical sites. Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m

findingsBetween Oct 1, 2015, and Feb 11, 2016, 957 individuals were randomly assigned (102-103 participants per active treatment group and 136 in the pooled placebo group). Mean baseline characteristics included age 47 years, bodyweight 111·5 kg, and BMI 39·3 kg/m

interpretationIn combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses.

fundingNovo Nordisk A/S.

Indexed as

AdultBlood GlucoseBody Mass IndexDouble-Blind MethodFemaleGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsInjections, SubcutaneousLiraglutideMaleMiddle AgedObesityPlacebosBlood GlucoseGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsLiraglutidePlacebosSemaglutide

Identifiers

PMID30122305
OpenAlexW2885588864

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.